AKBA - CIK 0001517022
Akebia Therapeutics, Inc. (AKBA) reported net income of -$5.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$5.30M | +92.4% |
| FY 2024 | -$69.40M | -33.7% |
| FY 2023 | -$51.90M | +44.9% |
| FY 2022 | -$94.20M | +66.6% |
| FY 2021 | -$282.00M | +26.7% |
| FY 2020 | -$384.84M | -37.6% |
| FY 2019 | -$279.66M | -94.8% |
| FY 2018 | -$143.59M | -94.9% |
| FY 2017 |
Akebia Therapeutics, Inc. (AKBA) reported net income of -$5.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Akebia Therapeutics, Inc.'s net income grew from -$8.20M to -$5.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$73.67M |
| +45.7% |
| FY 2016 | -$135.75M | -123.6% |
| FY 2015 | -$60.72M | -63.9% |
| FY 2014 | -$37.03M | -181.3% |
| FY 2013 | -$13.17M | -60.7% |
| FY 2012 | -$8.20M | - |